AU2002367172A1 - 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents - Google Patents
2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agentsInfo
- Publication number
- AU2002367172A1 AU2002367172A1 AU2002367172A AU2002367172A AU2002367172A1 AU 2002367172 A1 AU2002367172 A1 AU 2002367172A1 AU 2002367172 A AU2002367172 A AU 2002367172A AU 2002367172 A AU2002367172 A AU 2002367172A AU 2002367172 A1 AU2002367172 A1 AU 2002367172A1
- Authority
- AU
- Australia
- Prior art keywords
- prolylpeptidase
- inducers
- diamino
- apoptosis
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34304701P | 2001-12-21 | 2001-12-21 | |
| US60/343,047 | 2001-12-21 | ||
| PCT/US2002/041146 WO2003055489A1 (en) | 2001-12-21 | 2002-12-20 | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002367172A1 true AU2002367172A1 (en) | 2003-07-15 |
Family
ID=23344452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002367172A Abandoned AU2002367172A1 (en) | 2001-12-21 | 2002-12-20 | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002367172A1 (en) |
| WO (1) | WO2003055489A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| NZ537752A (en) | 2002-07-29 | 2006-12-22 | Rigel Pharmaceuticals Inc | Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases |
| ES2421139T3 (en) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| DE602004032446D1 (en) * | 2003-08-07 | 2011-06-09 | Rigel Pharmaceuticals Inc | 2,4-PYRIMIDINDIAMIN COMPOUNDS AND USES AS ANTIPROLIFERATIVE AGENTS |
| EP1694652A1 (en) | 2003-12-19 | 2006-08-30 | Rigel Pharmaceuticals, Inc. | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
| WO2005118544A2 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| US7557207B2 (en) | 2004-11-24 | 2009-07-07 | Rigel Pharmaceuticals, Inc. | Spiro 2,4-pyrimidinediamine compounds and their uses |
| ES2337496T3 (en) | 2005-01-19 | 2010-04-26 | Rigel Pharmaceuticals, Inc. | PROFESSIONALS OF 2,4-PYRIMIDINDIAMINE COMPOUNDS AND THEIR USES. |
| US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| CN100387602C (en) * | 2005-07-08 | 2008-05-14 | 张晴龙 | Chelerythrine compound and its preparing method |
| WO2008051547A1 (en) | 2006-10-23 | 2008-05-02 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
| JP5713367B2 (en) | 2010-06-04 | 2015-05-07 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Aminopyrimidine derivatives as LRRK2 modulators |
| BR112013011600B1 (en) | 2010-11-10 | 2022-01-11 | Genentech, Inc | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES, THEIR USE AND COMPOSITION INCLUDING THEM |
| RS60186B1 (en) | 2011-04-29 | 2020-06-30 | Penn State Res Found | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy |
| WO2013123401A1 (en) * | 2012-02-17 | 2013-08-22 | Abbvie Inc. | Diaminopyrimidines useful as inhibitors of the human respiratory syncytial virus (rsv) |
| CN103408501B (en) * | 2013-08-14 | 2016-03-09 | 合肥医工医药有限公司 | Benzylpyrimidine derivative, its preparation method and medicinal use thereof |
| CN106362696A (en) * | 2016-10-17 | 2017-02-01 | 江苏理工学院 | Preparation method and application of surface modified nano aluminum oxide |
| CN111122523B (en) * | 2019-12-06 | 2021-09-28 | 山西大学 | Quick recognition Ag+Cys-combined molecular logic gate with three-phase output function and construction method thereof |
| CN111620852B (en) * | 2020-01-19 | 2023-05-09 | 镇江植生源农业科技有限公司 | 5-chloro-pyrimidine-2, 4-diamine compound, and preparation method and application thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0002341B1 (en) * | 1977-11-28 | 1982-01-20 | Barry Boettcher | Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| US6485955B1 (en) * | 1997-10-06 | 2002-11-26 | The Trustees Of Tufts University | Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease |
| DE69905306T2 (en) * | 1998-03-27 | 2003-11-27 | Janssen Pharmaceutica Nv | HIV-inhibiting pyrimidine derivatives |
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| CN100480242C (en) * | 2001-05-29 | 2009-04-22 | 舍林股份公司 | CDK-inhibitory pyrimidines, and production and use thereof as pharmaceutical agents |
-
2002
- 2002-12-20 AU AU2002367172A patent/AU2002367172A1/en not_active Abandoned
- 2002-12-20 WO PCT/US2002/041146 patent/WO2003055489A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003055489A1 (en) | 2003-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002364211A1 (en) | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents | |
| AU2002361846A1 (en) | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents | |
| AU2002367172A1 (en) | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents | |
| AU2002339157A1 (en) | Inhibitors of the notch signalling pathway for use in the treatment of cancer | |
| IL157425A0 (en) | Treatment of solid tumours with paramycin derivatives | |
| WO2003073999A3 (en) | Pini-modulating compounds and methods of use thereof | |
| AU2002258399A1 (en) | Use of trail and antiprogestins for treating cancer | |
| AU2002364364A1 (en) | Method of treating apoptosis and compositions thereof | |
| WO2003074550A3 (en) | Pin1-modulating compounds and methods of use thereof | |
| AU6048201A (en) | Quinazoline derivatives for the treatment of tumours | |
| AU2002252456A1 (en) | Combination treatment of pancreatic cancer | |
| AU2002340168A1 (en) | Treatment of prostate cancer by inhibitors of ncam2 | |
| HK1068551A1 (en) | Substituted benzimidazole compounds and their use for the treatment of cancer | |
| AU2002252227A1 (en) | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | |
| MXPA03008582A (en) | Agents and methods for treatment of cancer. | |
| AU2001266838A1 (en) | Inhibitors of matriptase for the treatment of cancer | |
| AU2003249713A1 (en) | 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis | |
| IL145397A0 (en) | Compositions and methods for treatment of cancer | |
| PL368035A1 (en) | Compositions and methods for the treatment of cancer | |
| AU2001232060A1 (en) | Use of cyp1b1 inhibitors for treating cancer | |
| AU2576901A (en) | Agents and methods for the treatment of proliferative diseases | |
| AU2002366195A1 (en) | Use of bisindolmaleimide and gemcitabine for the treatment of cancer | |
| AUPR644301A0 (en) | Method and composition for treatment of cancer | |
| AU2003284787A1 (en) | Inhibitor of angiogenesis and kit for treating cancer comprising the inhibitor | |
| AU2002350432A1 (en) | Combination of cimetidine and cysteine derivatives for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |